BlackRock
MRTX

BlackRock’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BlackRock’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,866,202
Closed -$227M – 5476
2023
Q4 		$227M Buy
3,866,202
+321,891
+9% +$18.1M 0.01% 1567
2023
Q3 		$154M Buy
3,544,311
+226,292
+7% +$8.08M ﹤0.01% 1717
2023
Q2 		$120M Buy
3,318,019
+81,140
+3% +$3.34M ﹤0.01% 1924
2023
Q1 		$120M Buy
3,236,879
+573,957
+22% +$25.8M ﹤0.01% 1892
2022
Q4 		$121M Buy
2,662,922
+235,171
+10% +$15.2M ﹤0.01% 1874
2022
Q3 		$170M Buy
2,427,751
+17,385
+0.7% +$1.29M 0.01% 1601
2022
Q2 		$162M Sell
2,410,366
-387,272
-14% -$24.6M 0.01% 1683
2022
Q1 		$230M Buy
2,797,638
+40,963
+1% +$4.19M 0.01% 1572
2021
Q4 		$404M Buy
2,756,675
+98,465
+4% +$15.3M 0.01% 1201
2021
Q3 		$470M Sell
2,658,210
-369,295
-12% -$59.4M 0.01% 1024
2021
Q2 		$489M Sell
3,027,505
-1,546,086
-34% -$248M 0.01% 1025
2021
Q1 		$783M Buy
4,573,591
+293,179
+7% +$58M 0.02% 703
2020
Q4 		$940M Buy
4,280,412
+869,526
+25% +$188M 0.03% 555
2020
Q3 		$566M Sell
3,410,886
-36,751
-1% -$5.03M 0.02% 680
2020
Q2 		$394M Buy
3,447,637
+471,467
+16% +$45.7M 0.02% 858
2020
Q1 		$229M Buy
2,976,170
+219,471
+8% +$19.7M 0.01% 1060
2019
Q4 		$355M Buy
2,756,699
+23,429
+0.9% +$2.26M 0.01% 1066
2019
Q3 		$213M Buy
2,733,270
+197,236
+8% +$18.5M 0.01% 1359
2019
Q2 		$261M Buy
2,536,034
+199,939
+9% +$15.6M 0.01% 1229
2019
Q1 		$171M Buy
2,336,095
+283,146
+14% +$19.3M 0.01% 1523
2018
Q4 		$87.1M Buy
2,052,949
+474,097
+30% +$18.9M ﹤0.01% 1899
2018
Q3 		$74.4M Buy
1,578,852
+127,638
+9% +$7.11M ﹤0.01% 2162
2018
Q2 		$71.5M Buy
1,451,214
+816,980
+129% +$30.9M ﹤0.01% 2147
2018
Q1 		$19.5M Buy
634,234
+123,872
+24% +$3.44M ﹤0.01% 2790
2017
Q4 		$9.31M Buy
510,362
+186,419
+58% +$2.89M ﹤0.01% 3181
2017
Q3 		$3.79M Buy
323,943
+25,094
+8% +$145K ﹤0.01% 3544
2017
Q2 		$1.09M Sell
298,849
-586,749
-66% -$2.25M ﹤0.01% 3832
2017
Q1 		$4.61M Buy
885,598
+881,699
+22,613% +$4.83M ﹤0.01% 3402
2016
Q4 		$19K Sell
3,899
-166
-4% -$903 ﹤0.01% 3271
2016
Q3 		$27K Hold
4,065
– – ﹤0.01% 3212
2016
Q2 		$22K Buy
4,065
+3,337
+458% +$53.2K ﹤0.01% 3246
2016
Q1 		$15K Buy
728
+394
+118% +$8.81K ﹤0.01% 2987
2015
Q4 		$11K Buy
334
+150
+82% +$5.3K ﹤0.01% 2865
2015
Q3 		$6K Hold
184
– – ﹤0.01% 2958
2015
Q2 		$6K Sell
184
-54
-23% -$1.59K ﹤0.01% 3086
2015
Q1 		$7K Buy
+238
New +$5.58K ﹤0.01% 2932
2014
Q2 		– Sell
-19
Closed – – 3237
2014
Q1 		$0 Buy
+19
New +$395 ﹤0.01% 3177

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BlackRock's MRTX Position: Q1 2024 in Review

BlackRock sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 3,866,202 shares — an estimated $227M sold.

BlackRock first reported a position in MRTX in Q1 2014 and held it in 37 quarters. The position peaked at $940M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • BlackRock reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • BlackRock sold 3,866,202 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $227M.
  • BlackRock first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 37 quarters.
  • BlackRock's Mirati Therapeutics, Inc. Common Stock position peaked at $940M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.